Johnson & Johnson’s push into new medicines has helped it offset the loss of revenue from its blockbuster Stelara treatment, according to Guggenheim which upgraded the stock to Buy. The brokerage raised its target price to $206 from $167,

Johnson & Johnson’s JNJ multibillion-dollar immunology drug, Stelara, lost patent exclusivity in the United States this year. It is approved for treating moderate-to-severe plaque psoriasis, active psoriatic arthritis,

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease (IBD) and, in doing so, achieved a first for the IL-23 inhibitor drug c | The FDA has approved a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis (UC).

Johnson & Johnson (JNJ) stock jumps as analysts upgrade outlooks and highlight new medicines set to offset Stelara losses. Discover what’s driving this healthcare giant’s momentum.

MedImpact Holdings is planning to offer an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than Stelara. The biosimilar, distributed by Anda, an affiliate of Teva Pharmaceuticals USA, will be available for direct purchase from MedImpact ...

A large percentage of patients starting a medication take expensive brand-name products instead of biosimilars, even as health plans and PBMs work on converting existing brand-name prescriptions to biosimilars.

ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.

Johnson & Johnson (JNJ) stock gains as Guggenheim upgrades the company to Buy highlighting its Innovative Medicine pipeline. Read more here.

Scripius removed Stelara (ustekinumab) from its large employer formulary and replaced it with Pyzchiva (ustekinumab-ttwe) and Selarsdi (ustekinumab-aekn)